The TSX Venture Exchange has accepted for filing the qualifying transaction of Vimy Pharmaceuticals Corp. (formerly Harmony Acquisitions Corp.), as described in its filing statement dated Nov. 6, 2026. As a result, at the opening on Nov. 17, 2026, Vimy Pharmaceuticals will no longer be considered as a capital pool company. The qualifying transaction consisted of the arm's-length acquisition of all of the issued and outstanding common shares in the capital of Vimy Pharmaceuticals Inc. (Vimy Pharma) pursuant to the acquisition agreement dated Sept. 28, 2026, in exchange for 27,168,142 postconsolidated shares at a deemed value of $3 per share for aggregate gross proceeds of $81,504,426. The company consolidated its shares on a one-new-for-49.6-old basis. The shares will be exchanged on a one-for-one basis on a postconsolidated basis. For additional information, refer to the company's news releases dated Sept. 28, 2026, and Nov. 12, 2026, and its filing statement dated Nov. 6, 2026, which is filed on SEDAR+.

In connection with the closing of the transaction, Vimy Pharma closed its previously announced brokered concurrent financing of $14,539,062.

A non-arm's-length finder's fee totalling 208,333 shares has been paid related to the transaction.

The exchange has been advised that the above transactions have been completed.